Abstract： Drug-resistant tuberculosis has gradually become a global public health problem that is gaining attention acround the world. A new anti-tuberculosis drug, bedaquiline (BDQ), has showed significant therapeutic efficacy in drug-resistant TB. However, since the first case of BDQ resistance was reported in 2014, its resistance has gradually increased. In this article, we reviewed the antimicrobial properties of BDQ, resistance characteristics and molecular mechanisms of BDQ resistance, and we also discussed the strategies to avoid the occurrence of BDQ resistance.